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INTRODUCTION 
The emergence of resistance to drugs used to treat tuberculosis (TB), 
and particularly Multidrug-resistant TB (MDR-TB), which is defined to 
resistance to atleast Isoniazid and Rifampicin with or without resistance to 
other drugs
1
, has become a significant health problem in a number of countries 
and an obstacle to effective TB control
1
.    
         Among all incident TB cases globally, 3.6% (95% CI: 3.0–4.4) are 
estimated to have MDR-TB
2
. China and India account for almost 50% of the 
estimated global number of incident MDR-TB cases
2
. High MDR-TB mortality 
can be addressed through adequate prevention, diagnosis, treatment and care. 
Since the vast majority of cases are undetected and do not receive adequate 
care, we expect a global decline in MDR-TB mortality as the coverage and 
quality of DST and treatment programmes improve globally. Systematic 
infection control measures have the potential to greatly reduce transmission in 
hospitals and other congregate settings, and therefore the mortality of, HIV-
associated MDR-TB
2
. 
 
 
       
Distribution of proportion of MDR-TB among new TB cases, 1994–20092. 
 
Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global 
report on surveillance and response. WHO/HTM/TB/2010.3 
 
 
  
Distribution of proportion of MDR-TB among previously treated TB 
cases, 1994–20092. 
 
Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global 
report on surveillance and response. WHO/HTM/TB/2010.3 
 
 
India is one of the high burden countries for MDR-TB
2
.The prevalence 
of Multi-drug resistant (MDR-TB) are found to be less than 1%-3% in new 
cases and 12% in re-treatment cases
1, 3, 4
. Specific measures are being taken 
within the Revised National Tuberculosis Control Programme (RNTCP) to 
address the MDR-TB problem through appropriate management of patients by 
implementing a standardized category IV (DOTS PLUS) regimen and 
strategies to prevent the propagation and dissemination of MDR-TB
1
. 
Initiation of MDR-TB treatment by DOTS PLUS therapy was started at 
Ahmedabad, Gujarat in August 2007
5
.subsequently it was started in other 
districts of India in a phased manner. The programme was started at January 
2009 in Tamilnadu. The only functional DOTS PLUS site in Tamilnadu is 
Government Hospital Of Thoracic Medicine, Tambaram Sanatorium
5
. 
 
                           GHTM, TAMBARAM SANATORIUM 
DOTS PLUS WARD 
GTHM, TAMBARAM SANATORIUM 
      
          While MDR-TB control in 2010 was estimated to re-quire less than 20% 
of all TB control programme budgeted costs globally in 2009, by 2015 this 
proportion is expected to reach 50%
2
. In ﬁve of these countries (the Democratic 
Republic of the Congo, India, Nigeria, Pakistan and Uzbekistan), more than 
two-thirds of the planned budget represents a funding gap
2
. 
Since treatment of MDR-TB is very critical in preventing the spread of 
resistant strains in the community and to reduce the emergence of XDR-TB 
which is a extremely fatal disease and in helping to reduce the economic 
burden to the developing country like India in an indirect way, our aim was to 
study the outcome of 100 MDR-TB patients one year after starting DOTS 
PLUS therapy who are enrolled from May 2009 to May 2010 at GHTM, 
Tambaram Sanatorium. 
This will give an interim outcome and effectiveness of DOTS PLUS 
programme in Tamilnadu. The profile of patients entering DOTS PLUS 
programme in Tamilnadu are also studied.The complexity of disease and 
treatment and development of XDR-TB among treatment failures are important 
issues to be addressed and should be carefully followed up. 
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REVIEW OF LITERATURE 
Multidrug resistant tuberculosis: 
MDR-TB is defined as resistance to Isoniazid and Rifampicin, with or 
without resistance to other anti-TB drugs
1
. 
Causes of drug resistant tuberculosis: 
Drug-resistant TB has microbial, clinical, and programmatic causes. 
From a microbiological perspective, the resistance is caused by a genetic 
mutation that makes a drug ineffective against the mutant bacilli. An 
inadequate or poorly administered treatment regimen allows drug-resistant 
mutants to become the dominant strain in a patient infected with TB. However 
it should be stressed that MDR-TB is a man-made phenomenon – poor 
treatment, poor drugs and poor adherence lead to the development of MDR-
TB
1
.   
Magnitude of MDR-TB problem in India: 
The prevalence of multi-drug resistant TB (MDR-TB) is less than 1% to 
3% in new cases and around 12% in re-treatment cases
1, 3, 4
.   
A retrospective analysis of various randomized clinical trials conducted 
by the TRC with various Rifampicin containing regimens in the initial 
intensive phase, and with and without Rifampicin in the continuation phase, 
revealed an overall emergence of resistance to Rifampicin in only 2% of 
patients, Despite a high level (18%) of initial resistance to isoniazid, either 
alone or in combination with other anti-TB Drugs
1, 6
. 
Case definitions:  
MDR-TB Suspect
1
:   
 Any TB patient who fails an RNTCP Category I or III treatment 
regimen;   
 Any RNTCP Category II patient who is sputum smear positive at the 
end of the fourth month of treatment or later; or  
 Close contacts of MDR-TB patients who are found to have smear 
positive pulmonary TB (PTB) disease 
Confirmed MDR-TB case
1
:   
An MDR-TB suspect who is sputum culture positive and whose TB is 
due to Mycobacterium tuberculosis that are resistant in-vitro to at least 
Isoniazid and Rifampicin (The culture and DST result being from an RNTCP 
accredited laboratory). Patients with are not MDR but have any Rifampicin 
resistance will also be treated with Cat IV regimen. 
Diagnostic examination
1
  
Presently conventional solid egg-based Lowenstein-Jensen (LJ) media 
will be used for primary culture at the RNTCP accredited laboratory. DST will 
be performed for streptomycin (S), isoniazid (H),rifampicin (R) and ethambutol 
(E) only.    
Multi-drug resistant tuberculosis and DOTS-Plus
1
: 
RNTCP has started Standardised Treatment Regimen (Cat IV-DOTS 
PLUS REGIMEN) for the treatment of MDR-TB cases (and those with 
Rifampicin resistance) under the programme.  Cat IV regimen comprises of 6 
drugs- kanamycin, levofloxacin, ethionamide, pyrazinamide, ethambutol and 
cycloserine during 6-9 months of the Intensive Phase and 4 drugs- ofloxacin 
(levofloxacin), ethionamide, ethambutol and cycloserine during the 18 months 
of the Continuation Phase. p-aminosalicylic acid (PAS) is included in the 
regimen as a substitute drug if any bactericidal drug (K, Ofl, Z and Eto) or 2 
bacteriostatic (E and Cs) drugs are not tolerated.   
RNTCP CATEGORY IV REGIMEN: 6 (9) Km Ofx (Lvx) Eto Cs Z E / 
18 Ofx (Lvx) Eto Cs E. 
 
 
 Dosage and weight band recommendations
1
: 
S.NO Drugs 16-25 Kgs 26-45 Kgs >45 Kgs 
1 KANAMYCIN 500 mg 500 mg 500 mg 
2 LEVOFLOXACIN 200 mg 500 mg 750 mg 
3 ETHIONAMIDE 375 mg 500 mg 750 mg 
4 ETHAMBUTOL 400 mg 800 mg 1000 mg 
5 PYRAZINAMIDE 500 mg 1250 mg 1500 mg 
6 CYCLOSERINE 250 mg 500 mg 750 mg 
7 PAS 5 gm 10 gm 12 gm 
8 PYRIDOXINE 50 mg 100 mg 100 mg 
 
 
 
 
Treatment Outcomes
1
  
Cure: An MDR-TB patient who has completed treatment and has been 
consistently culture negative (with at least 5 consecutive negative results in the 
last 12 to 15 months). If one follow-up positive culture is reported during the 
last three quarters, patient will still be considered cured provided this positive 
culture is followed by at least 3 consecutive negative cultures, taken at least 30 
days apart, provided that there is clinical evidence of improvement.  
Treatment completed: An MDR-TB patient who has completed 
treatment according to guidelines but does not meet the definition for cure or 
treatment failure due to lack of bacteriological results.   
Death: An MDR-TB patient who dies for any reason during the course 
of MDR-TB treatment  
Treatment failure: Treatment will be considered to have failed if two 
or more of the five cultures recorded in the final 12-15 months are positive, or 
if any of the final three cultures are positive.   
Treatment default: An MDR-TB patient whose MDR-TB treatment 
was interrupted for two or more consecutive months for any reasons.   
Transfer out: An MDR-TB patient who has been transferred to another 
reporting unit (DOTS Plus site in this case) and for whom the treatment 
outcome is not known.  
Treatment stopped due to adverse drug reactions: A patient on 
MDR-TB treatment who develops severe adverse reactions and could not 
continue the MDR-TB treatment in spite of the management of the adverse 
reactions as per the defined protocols and decision has been taken by the 
DOTS-Plus site committee to stop treatment   
Treatment stopped due to other reasons: A patient on MDR-TB 
treatment who could not continue the MDR-TB treatment for any other medical 
reason (than adverse drug reactions), and a decision has been taken by the 
DOTS-Plus site committee to stop treatment.  
Switched to Category V treatment: A Category IV patient who during  
treatment is identified as an “XDR-TB suspect” and who is found to have 
XDR-TB on testing by an NRL, who subsequently has had their Category IV 
treatment stopped and RNTCP Category V treatment initiated.   
Still on treatment: An MDR-TB patient who, for any reason,  is still 
receiving  their RNTCP CAT IV treatment at the time of the submission of the 
RNTCP DOTS- Plus Treatment Outcome Report. 
DOTS PLUS treatment in Tamilnadu: 
DOTS PLUS treatment was started in India at Ahmedabad, Gujarat at 
August 2007
5
.susequently it was introduced in other states of India in a phased 
manner. The programme was started in Tamilnadu from January 2009 with 
Government Hospital Of Thoracic Medicine, Tambaram Sanatorium being the 
only functional DOTS PLUS site. In Tamilnadu it was started initially only in 4 
districts. Gradually further districts were included in the programme and by 
2011 all districts were covered in Tamilnadu. 
Accredited laboratory in Tamilnadu
5
: 
 IRL at Chennai has been accredited for Solid C & DST in January 2009.   
 CMC, Vellore laboratory has been accredited in January 2009. 
Literature review shows that: 
In a literature, Clin Infect Dis. (2008) 47 (4): 496-502
7
:   Assessment of 
treatment outcomes revealed that 86 patients (55%) were cured, 16 (10%) 
completed therapy, 10 (6%) died, 15 (10%) defaulted treatment, 22 (14%) 
experienced treatment failure, and 6 (4%) were transferred to another medical 
center. In total, 102 patients (66%) had favourable outcomes, and 53 (34%) had 
unfavourable outcomes. According to this study favourable outcome was about 
66%.But limitation in this study is that it does not show the co morbid factors 
and the factors that are associated with unfavourable outcomes.     
Leimane V et al 
8
 observed that, 135 (66%) patients were cured or 
completed therapy, 14 (7%) died, 26 (13%) defaulted, and treatment failed in 
29 (14%). Of the 178 adherent patients, 135 (76%) achieved cure or treatment 
completion. This study has shown good cure rate, low death rate. 
Shean KP et al
9  
observed that (49%) were cured or completed treatment, 
68 (14%) died, 144 (29%) defaulted from treatment, 27 (5%) failed, 10 (2%) 
transferred out and 3 (<1%) remained on treatment. Among 410 patients who 
had not transferred out or died, 281 (69%) had 2-year data available: 185 (66%) 
were cured or completed treatment, 32 (11%) were retreated for TB and 64 
(23%) died. This study review shows that defaulter rate (29%) has been quiet 
high, but failure rate is very low (5%). 
V.K. Arora et al 
10 
observed
 
that, off 66 patients included for analysis, 53 
(80.9%) became culture-negative, 77.3% of these within three months. Four 
(6.1%) failed to convert within nine months. Rest died or defaulted. Among 28 
patients completing two years of treatment, 67.9% were cured, 14.3% died, 
17.9% defaulted, but none failed treatment. Cycloserine had to be stopped in 
five patients, and kanamycin in three patients due to adverse effects. This 
review mentions about the drug toxicity profile and also defaulter rate was 
quiet high (17.9%).
 
 
 
WHO report on Global outcome of MDR-TB, 2010
2
: 
 In total, outcomes were reported for 1589 new cases and for 2911 
previously treated cases. These outcomes represent 8% of new and 14% of 
previously treated MDR-TB cases expected to have occurred among the TB 
cases notiﬁed by these countries in the same year2. Overall treatment success 
was 60% (95%CI: 55–66) after adjustment for clustering at country level. 
Among new cases, treatment success averaged to 64% (95%CI: 55–72), and 
8% died (95%CI: 5–11). Treatment success for previously treated cases was 
58% (95%CI: 52–64) and 13% died (95%CI: 10–15)2. 
This global report on MDR-TB outcome shows that worldwide the cure 
rate is 61%(after adjusting for clustering by country)
2
.Death rate is quiet low 
(8%) in new MDR-TB cases compared to previously treated cases where death 
rate is 13%
2
. 
Marie flament-saillour et al
11 
observed that, among 51, Patients were 
primarily
 
men (74.5%) with a median age of 45 yr (range, 20 to 78 yr). Thirty-
two
 
(62.7%) were foreign born, 21 (41.2%) had a low socioeconomic
 
status, 
19 (37.3%) had no stable housing, and eight (15.7%) were
 
HIV-co infected. 
The median duration of survival of MDR-TB cases was 30.7 mo (CI95, 25.2 to 
36.1). There was an excess mortality among patients
 
with MDR-TB compared 
with patients with drug-susceptible tuberculosis
 
(Logrank test 
= 15.45, p < 0.001). MDR-TB case-patients co infected
 
with HIV had a shorter 
duration of survival (median, 2.1 mo; CI95,
 
0.9 to 3.3) than did drug-susceptible 
HIV-co infected control-patients
 
(median > 36
 
mo). 
This study analyzed the socioeconomic status, HIV coinfection and 
showed that MDR-TB co infected with HIV had higher mortality compared to 
non HIV with MDR-TB. 
Orenstein EW et al
12 
observed that Individualised treatment regimens 
had higher treatment success (64%, 95% CI 59-68%) than standardised 
regimens (54%, 95% CI 43-68%), although the difference was not significant. 
 
We according to the programme are following standardised treatment 
regime for treatment of MDR-TB based on weight of the individual. Various 
studies have been done to assess the efficacy of standardised and individual 
regimen. But the study did not show any significant difference in the outcome. 
Holtz TH et al
13 
observed that, Mortality among MDR-TB defaulters 
was high. Interventions to reduce default from MDR-TB treatment should 
center on substance abuse treatment, patient education and support and 
improving provider-patient relationships. This study assessed the cause for 
mortality among MDR-TB patients and concluded that substance abuse 
treatment and health education is very much essential to create awareness and 
prevent the spread of disease and also to reduce defaulters and thereby reducing 
mortality due to the disease. 
So it is important to follow up the patients with MDR-TB and also to 
analyse the socio-economic and co morbid factors to know about the course of 
the disease, adverse effects of drugs, since it is very much essential to arrest the 
spread of resistant strains and to reduce the emergence of XDR-TB and help to 
decrease economic burden to the country in an indirect way. 
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AIM OF THE STUDY 
1)  To study the outcome of Multidrug-resistant tuberculosis (MDR-
TB), patients 1 year after starting on DOTS PLUS (CAT IV 
RNTCP) enrolled from May 2009 to May 2010 at Government 
Hospital of Thoracic Medicine, Tambaram Sanatorium. 
2) To analyze the factors associated with death and culture positivity 
at the end of one year. 
 
 
  
Materials & 
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MATERIALS AND METHODS 
STUDY DESIGN 
Prospective study 
INCLUSION CRITERIA:  
Culture proved 100 MDR-TB patients who were enrolled from May 
2009 to May 2010 and initiated on DOTS PLUS therapy at GHTM is followed 
up for the period of one year. 
EXCLUSION CRITERIA: 
1) Patients who are under 15 years of age 
2) History of more than 1 month treatment with any second line 
anti-TB drug. 
METHOD:  
         Data’s were recorded from TB.HIV.Information.System (t.h.i.s).Follow 
up of patients were based on RNTCP DOTS PLUS guidelines. The clinical and 
microbiological outcome at the end of one year and factors associated with 
death and culture positivity were analyzed using multi variate analysis. 
FOLLOW UP – AS PER DOTS PLUS GUIDELINES
1
: 
          The follow up of MDR-TB patients started on DOTS PLUS (CAT IV 
REGIMEN) will be mainly based on both microbiological and clinical criteria. 
The follow up will be done as per RNTCP DOTS PLUS guidelines. 
1. Smear and culture examination:     
Four sputum specimens will be collected and examined by smear and 
culture at least 30 days apart from the 3
rd
 to 7
th
 month of treatment   (i.e. at the 
end of 3, 4, 5, 6, 7 months) and at 3 monthly intervals from the 9
th
 month 
onwards till the completion of treatment (i.e. at the end of 9, 12, 15, 18, 21, 24).  
The sputum for AFB smear will be collected and examined at respective 
DMC/DTC. The sputum for AFB culture will be collected and transported in 
CPC bottles from the respective DTC to the RNTCP accredited laboratory
1
. 
 The importance of the sputum examination during treatment needs to be 
emphasized, since the most important objective evidence of improvement is the 
conversion of sputum smear and culture to negative. Patients will be considered 
culture converted after having two consecutive negative cultures taken at least 
one month apart. Time to culture conversion is calculated as the interval 
between the date of MDR-TB treatment initiation and the date of the first of 
these two negative consecutive cultures (the date that the sputum specimens are 
collected for culture should be used). Similarly patients will be considered 
smear converted after having two consecutive negative smears taken at least 
one month apart. Two separate indicators, one based on sputum smears and the 
other on cultures will be calculated and interim reports will be given by the 
state level DOTS Plus site for smear and culture after completing 6 months and 
12 months of treatment. Though smear conversion can be taken as an indicator, 
culture conversion which reflects viability of tubercle bacilli, is more sensitive 
and is necessary to monitor progress in MDR-TB patients. Good quality 
sputum is essential to get proper results
1
. 
2. Clinical monitoring:  
Every month during intensive phase and 3 monthly once during 
continuation phase by the DTO and if patient fell ill during the course of 
treatment it will be intimated to dots plus site and if necessary patient will be 
admitted. 
1. Weight of the patient during every visit. 
2. Serum Creatinine: Every month for first three months and 
then every 3 months till patient is receiving kanamycin. 
3. Chest X-ray: During end of Intensive phase and end of 
treatment and when clinically indicated.   
4. Looking for any adverse effects due to drugs. 
Socio-demographic and co morbid factors: 
Further, Socio-demographic Profile of patients entering into DOTS 
PLUS treatment in Tamilnadu from May 2009 to May 2010 and also the co 
morbid factors associated with death, culture positivity at the end of one year 
were analyzed using multivariate analysis.  
  
 
ETHICAL JUSTIFICATION 
The various investigations and procedures that will be used in this study 
will be as per RNTCP guidelines. The identity of each patient will be kept 
confidential. This study will not violate medical ethics in anyway and it will 
help to know the outcome of MDR-TB treatment in Tamilnadu.     
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OBSERVATIONAND RESULTS 
             The study on the OUTCOME OF MULTIDRUG RESISTANT 
TUBERCULOSIS PATIENTS STARTED ON DOTS PLUS (CAT-IV RNTCP 
REGIMEN) AT GOVERNMENT HOSPITAL OF THORACIC MEDICINE, 
TAMBARAM SANATORIUM between May 2009 to May 2010 and the 
following observation were made. 
 OUTCOME AT THE END OF 1 YEAR: 
 Off the 100 patients analysed in our study who were started on treatment, 
64% remained culture negative at the end of 1 year,15% died ,3% defaulted 
and 18% remain culture positive at the end of 1 year.          
ONE YEAR OUTCOME OF MDR-TB PATIENS:  TABLE -1 
 
TOTAL NUMBER OF MDR-TB PATIENTS 
 
100 
 
CULTURE NEGATIVE AT THE END OF ONE 
YEAR 
 
64 
 
 
CULTURE POSITIVE AT THE END OF ONE 
YEAR 
 
18 
 
NUMBER OF PATIENTS DIED WITHIN ONE 
YEAR 
 
15 
 
DEFAULTERS WITHIN ONE YEAR 
 
3 
 
  
 
ONE YEAR OUTCOME OF MDR-TB PATIENTS 
CHART-1 
 
 
 
 
 Off the 64 culture converted patients, 40 patients converted in 3months after 
initiation of treatment.4 patients in 4 months, 6 patients in 5 monts,8 
patients  in 6 months,2 patients in 7 months,2 patients in 9 months and 2 
patients in 12 months. 
CULTURE CONVERTED PATIENTS WITHIN ONE YEAR = 64 
TABLE – 2 
 
No. of patients Culture converted in 
3 months 
40 (62.5%) 
4 months 4 (6.25%) 
5 months 6(9.37%) 
6 months 8(12.5%) 
7 months 2(3.12%) 
9 months 2(3.12%) 
12 months 2(3.12%) 
 
 
 
  
 In our study among 100 MDR-TB patients, 20 were diabetics who were 
started on DOTS PLUS treatment.  
CHART-2 
 
 
                 
 
  
Among 100 MDR-TB patients, HIV coinfection was present in only 2 patients 
in our study. 
CHART-3 
                     
 
 
 
  Socio-demographic profile of 100 patients: 
 Among 100 patients, 82 patients were male, remaining 18 were females 
in our study. 
CHART-4 
 
 
 
 
  Off the 100 patients, 38 patients were in the age group of 15 – 34 years, 47 
patients were in 35-54 years group, 15 patients were above 55 years of age. 
                    
AGE WISE INCIDENCE OF MDR-TB 
CHART-5 
 
 
 
  
  Off the 100 patients, 58 patients belongs to <45 kg weight band, 42 patients 
belongs to >45 kg weight band in our study group. 
 
PRE-TREATMENT WEIGHT AMONG 100 MDR-TB PATIENTS 
CHART-6 
      
 
 
 
 
  
 Off the 100 patients, 40 were tobacco users and 29 were alcoholic and 28 
were both in our study group. 
 
TOBACCO AND ALCOHOL USE AMONG MDR-TB PATIENTS 
CHART-7 
       
 
 
  In our study group of 100 patients, 69 patients were from rural area and 31 
from urban area. 
RESIDENTIAL STATUS OF MDR-TB PATIENTS 
CHART-8 
     
 
 
 
 
  Further factors associated with death and culture positivity were 
analyzed:  
 Out of 15 who died 26% (4 patients) were diabetics and 53 % (8 patients) 
were resistant to (H, R, S, and E). Among the culture positives 5% (1 
patient) were diabetic, 53% (10 patients) were resistant to  (H, R, S, and 
E).Among  culture negative patients at 1 year, 23 %(15 patients) were 
diabetic and 48% (31 patients)were (H,R,S,E) resistant.  
 
TABLE -3 
 
 
CHARACTERISTICS 
DIED 
TOTAL=15 
CULTURE 
POSITIVE 
PATIENTS 
TOTAL=18 
CULTURE 
NEGATIVE 
PATIENTS 
TOTAL=64 
DIABETES 4(26%) 1(5%) 15(23%) 
H,R,S,E RESISTANCE 8(53%) 10(53%) 31(48%) 
 
 
            
  
DIABETES AND HRSE RESISTANCE AMONG 3 GROUPS 
CHART-9        
 
 
 
 
  
 Among 15 patients who died, 14 patients (93%) were in the <45kg weight 
band. Among 18 culture positive patients at the end of 1 year, 15 were 
(83%) in the <45 weight band. Only 43% were in <45 kg weight band 
among culture negative patients. 
 
TABLE - 4 
CHARACTERISTICS 
DIED 
N=15 
CULTURE 
POSITIVE 
N=18 
CULTURE 
NEGATIVE 
N=64 
WEIGHT < 45 KGS 14(93%) 15(83%) 28(43%) 
 
 
 
 
 
             
 
PREVALANCE OF WEIGHT AMONG 3 GROUPS 
CHART – 10 
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DISCUSSION 
This study based on 100 patients in Tamilnadu who were started on 
standardized DOTS PLUS regimen recommended by RNTCP for the treatment 
of MDR-TB appears to be effective in terms of high culture conversion rate 
(64%),low defaulter rate(3%) at the end of 1 year. Death rate is 15%.Further, 
18% of patients remain culture positive at the end of 1 year (TABLE & 
CHART-1). 
Study done by V.K Arora et al observed that MDR-TB patients achieved 
good results with a sputum culture conversion rate of 80.9% and cure rate of 
67.9% with no failures
10
.  Pauline Joseph et al observed that standardized  
regimen recommended by RNTCP  for  the  treatment of MDR-TB cases  in  
India appears  to be effective  in  terms of high culture conversion, high cure 
(66%) and low death (8%)
14. 
Other studies conducted across the country showed similar results. 
Singla et al observed 61% cure rate in a study conducted at New Delhi
15. 
Malla 
et al also observed 70% cure rate in a study conducted at Nepal
16. 
 In contrast, Suarez PG et al observed only 48 per cent favourable 
response in Peru using a standardized regimen for chronic TB patients with 
MDR-TB
17
. 
 Global report on MDR-TB outcome shows that worldwide the cure rate 
is 61 %( after adjusting for clustering by country)
2
.Our results showed 64% 
culture conversion rate at the end of 1 year using standardized DOTS PLUS 
regimen as per RNTCP guidelines. 
In our study among 64 culture converted patients, 40 (62.5%) patients 
achieved culture conversion at the end of 3 months.4 (6.25%) patients in 4 
months,6(9.37%) patients in 5 months,8(12.5%) patients in 6 months and 2 
(3.12%) patients in 7,9 and 12 months. This shows that most of the culture 
conversion occurs in 3 months after initiating treatment (TABLE-2). 
Pauline Joseph et al observed that, Time to culture conversion was 2 
months or less for 31 (82%) patients. By 6 months, 35 (92%) patients had 
culture converted in a study conducted in Tamilnadu
14. 
V K Arora et al observed that, Out of the 66 patients included for 
analysis, 53(80.9%) patients achieved sputum culture conversion within nine 
months. Notably, among these 53 patients, 77.4% patients became culture-
negative within three months and 92.5% became culture-negative within six 
months of treatment. Another four (6.1%) patients remained culture-positive 
even after receiving treatment for more than nine months
10
. 
Holtz PH et al observed that, under programme conditions in Latvia, 
most patients with MDRTB achieved sputum culture conversion within 12 
weeks of starting treatment. Chest radiography and sputum culture drug 
susceptibility testing can assist physicians in predicting which patients will 
convert more slowly
18
. 
Literature review shows that, culture conversion results are similar to 
our study that most of the culture conversion occurs within 12 weeks of 
initiating treatment.
.
 
In our study, Adherence level was good since defaulter rate was 
3%.Among that 3 patients 1 patient has been traced and counselled and has 
been reregistered and started on DOTS PLUS therapy.1 patient has gone for 
native medicine treatment.  
Arora et al observed defaulter rate of about 17.9% which is quiet high
10
. 
Similarly Pauline et al observed 13% defaulter rate
14
. Kwonjune J Seung et al 
observed that only one patient had defaulted in a study conducted across 
southern Africa where there is high HIV prevalence
19
. So, reviewing the studies 
shows that defaulter rate is low in our study which is very good. 
 Adherence  to treatment was  attained  by  strong  health  education  to 
the patient and  their family members prior  to starting treatment  and  at  
periodic  intervals,  decentralized DOT  supplemented  with  rigorous  
supervision  by experienced  health  care  staff,  intense  monitoring, prompt 
identification and management of adverse drug reactions, and  involvement of 
community and  family in providing DOT
14
. 
In our study, 15 patients have died within one year of starting MDR-TB 
treatment which should be evaluated carefully. 
According to the Global outcome report on MDR-TB, death rate is 8% 
for new cases and 13% for previously treated cases
2
. Compared to new cases 
mortality is high in previously treated cases. 
  Study by V.K Arora et al observed 14.3% death rate
10
, while Pauline et 
al showed 8% death rate
14.
 Kwonjune J Seung et al observed 29% death rate, 
but in this study HIV coinfection was very high (74%)
19
. 
The cause for high death rate in our study should be evaluated and 
carefully followed up. 
In our study, serious adverse events requiring stoppage of drugs for 
patients who has been started on DOTS plus is nil. Except for minor reactions 
which necessitated symptomatic treatment, major reactions are nil.   
Reviewing literatue, V.K Arora et al observed 15.1% adverse reactions 
which required drug modification
10
. 
Pauline et al observed 58% severe adverse reactions
14
 which required 
drug modification. 
        Reported minor events in our study group were nausea, vomiting, 
giddiness which responded to symptomatic treatment. 
Our findings are similar to the results across the globe, observed in a 
Meta analysis which states that, Data on adverse events collected from five 
DOTS-Plus sites in Estonia, Latvia, Peru (Lima), the Philippines (Manila) and 
the Russian Federation (Tomsk Oblast) shows that among 818 patients enrolled 
on MDR-TB treatment only 2% of patients stopped treatment. The study shows 
that adverse events are manageable in the treatment of MDR-TB in resource-
limited settings provided that standard management strategies are applied
20
. 
In our study group, 18 patients were Culture positive at the end of one 
year (TABLE & CHART-1). 
V K Arora et al observed, Fifty-two patients enrolled upto December 
2004 who had completed more than one-year treatment, for interim treatment 
outcome. Thirteen patients required intensive phase of more than six months 
(mean duration of 7.4 months). Thirty-six (69.2%) were likely to have been 
cured (clinically improving and sputum culture continued to be negative at one 
year), six (11.5%) died, six (11.5%) defaulted, and four (7.7%) were likely to 
have failed treatment (sputum culture positive even after 12 months)
10
. 
13% failure rate has been observed in a study conducted by Pauline 
Joseph
14
.But this study comprises only 38 patients which is a limiting factor. 
So cause for this failure should be evaluated and followed up carefully. 
 
Further factors associated with death and culture positivity were analysed: 
20% patients were diabetics among the 100 MDR-TB patients 
(CHART-2). Only 4(26%) were diabetic among who died.Infact only one (5%) 
is diabetic in culture positive patients. (TABLE-3&CHART-9). 
Similar study in Tamilnadu during 2006-07 showed that off 38 MDR-
TB patients, 12(31.5%) were diabetics
14
.But this study does not analyse 
whether the patients who failed treatment and died during treatment are 
diabetics which is a limiting factor. 
A study conducted at Govt.Hospital of Thoracic Medicine, Tambaram 
has showed that T2DM was significantly associated (p<0.001) with male 
gender (odds ratio 2.976), Middle aged (0.701 and 95% CI- .238-2.068) and 
Elderly aged (Odds ratio 1.0) groups. Younger age, history of smoking or 
alcohol use, HIV infection, urban or rural locality was significantly associated 
with no history of T2DM
21
. 
      In our study, diabetes does not have significant impact on outcome of 
patients with MDR-TB.  
    
  
HIV and MDR-TB Coinfection: 
       In our study, only 2 out of 100 MDR-TB patients had HIV coinfection 
(CHART-3).Among the two, one has died. The association between HIV and 
MDR-TB is very low in our study. 
         The 4th report on anti-tuberculosis drug resistance reported a signiﬁcant 
association between HIV-positive status and MDR-TB in two settings: Latvia 
and Donetsk Oblast of Ukraine
2, 22
. 
        Although there appears to be an association between drug-resistant TB 
and HIV infection in some Eastern European countries, the data are still limited 
to be able to determine whether there is an overlap between the MDR-TB and 
HIV epidemics worldwide
2
. 
Pre-treatment Weight among MDR-TB patients: 
In our study, 93% of patients who died and 83% patients who were 
culture positive at the end of 1 year belong to < 45 kg weight band compared to 
only 43% in culture negative group (TABLE-4&CHART-10).  
Pauline et al observed 52% of MDR-TB patients are in <45kg band 
whereas 47% of patients belong to >45 kg weight band
14
.But this study does 
not analyse whether there is any association between low body weight and 
mortality and culture positivity.  
Mortality and culture positivity is high in patients who are <45 kgs in 
our study. Whether there is any association between low body weight and 
outcome of MDR-TB has to analysed and these patients should be monitored 
carefully. 
H,R,S,E resistance : 
Resistance to all H, R, S, E drugs has been observed in 53% of died and 
culture positive patients. It is seen in 43% of culture negative patients 
(TABLE-3&CHART-9).In our study ,resistance to all four first line drugs does 
not have any significant impact on outcome of MDR-TB patients. 
Socio-demographic profile of 100 MDR-TB patients: 
          In our study, 82 patients were males and remaining 18 were females 
(CHART-4). Similar study in Tamilnadu in 2006-07 observed 65% male 
patients and 35% female patients
14
. 
        Surprisingly V K Arora observed 54% male patients and 46% female 
patients in his study
10
.compared to other studies female ratio is high in this V K 
Arora study.        
              WHO global report states that, while males predominate among TB 
cases in most countries, this analysis suggests that the overall risk of 
harbouring MDR-TB strains is not inﬂuenced by sex2. Overall, combining data 
from these countries and territories (121 965; 58% males), and using the robust 
standard errors approach, the odds ratio of harbouring MDR-TB strains for 
female TB cases compared with male TB cases was 1.1 (95% CI: 0.9–1.4), 
showing no overall association between MDR-TB and the sex of the patient
2
. 
           In our study among 100 patients,38 patients belong to 15-34 yrs age 
group.47 were in 35-54 age group and 15 patients were in >55 yrs age group. 
Most of patients are in the <55 yrs group. 
  
Percentage of MDR-TB cases by age group among all TB cases 
            
 
Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global 
report on surveillance and response. WHO/HTM/TB/2010.3. 
 
 
 
In our study, about 40 patients were smokers and 29 patients were 
alcoholic. But it does not have any impact on outcome of MDR-TB. 
Difficulties in MDR-TB treatment programme: 
Operational constraints to establish MDR-TB treatment programmes 
include setting up proper linkages of peripheral DOT centres with central 
hospitals for referral/admission; problems in enrolling patients due to work 
compulsions and inability to comply with daily DOT for two years; lack of 
ready access to specialised laboratory facilities; arranging daily DOT therapy 
for two long years, especially on Sundays and other holidays; managing severe 
adverse drug reactions in field conditions. An MDR-TB treatment trial in 
Rwanda found that nearly 50% of eligible patients died or were lost to follow-
up while awaiting DST results from a distant reference laboratory
23
.  
Arranging proper training to medical, laboratory and non-medical 
workers for DOTS-Plus programmes is another operational constraint. 
Involvement of non-governmental organisation (NGOs) or local private 
practitioners proved to be of great help for some of these issues
10
. 
It has been acknowledged that good treatment is a pre-requisite to the 
prevention of emergence of resistance.RNTCP recognises that implementation 
of a good quality DOTS programme is the first priority for TB control in the 
country. Prevention of emergence of MDR-TB in the community is more 
imperative rather than its treatment
1
. 
Although the number of patients is 100, the early results have shown 
that use of carefully designed standardised treatment regimens with daily DOT 
for full duration, well-established NTP supported by highly motivated 
personnel and good linkage of peripheral and  referral central hospital, can 
provide satisfactory results and can be implemented as part of a successful 
DOTS programme. 
  From this study, it appears feasible to treat MDR-TB patients 
effectively in India on the predominantly ambulatory RNTCP standardized 
regimen.  
This study has given a broader view of patients who were started on 
DOTS PLUS therapy in Tamilnadu at the end of 1 year. Further the complexity 
of disease and treatment and development of XDR-TB among treatment 
failures are important issues to be addressed and should be carefully followed 
up. 
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                                            CONCLUSION 
Among 100 MDR-TB patients who were started on DOTS PLUS 
treatment in Tamilnadu, at the end of one year: 
* High mortality and culture positivity at the end of one year are 
found in patients who were <45 kgs.  
           Factors like Diabetes, Résistance to all first line drugs, Tobacco 
and Alcohol use and HIV does not have significant impact on 
outcome at the end of 1 year. 
 Major adverse events were rare and Adherence to treatment is 
good. 
* So it is very much essential to arrest the spread of resistant strains 
and to reduce the emergence of XDR-TB and help to decrease 
economic burden to the country in an indirect way. Timely 
identification of MDR-TB cases and adequately administered 
Category IV regimens are essential to stop primary transmission.  
DOTS/DOTS-Plus integration works synergistically to shut down 
all the potential sources of TB transmission. 
 
                
Global target -2015: 
While information available is growing and more and more countries are 
taking measures to combat MDR-TB, urgent investments in infrastructure, 
diagnostics, and provision of care are essential if the target established for 2015 
– the diagnosis and treatment of 80% of the estimated MDR/XDR-TB cases – 
is to be reached.                 
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     Proforma 
PROFORMA 
 
Name :    Age:                    Gender:   
  
Occupation    : 
 
Address    : 
 
Phone No                                   : 
 
Height/Weight                           :  
     
Smoking      :  Yes / No  
   Brand/quantity/Duration 
    If stopped when? 
 
Alcohol use             :  Yes / No  
  Brand/quantity/Duration 
                                                           If stopped when?   
 
Tobacco use                      : Chew/Snuff   No of times/day  
 COMORBID CONDITIONS: 
 
Pregnancy   : Yes/No 
 
Peptic ulcer   : Yes/No 
 
Bronchial Asthma  : Yes/No 
 
Hypertension    : Yes/No 
 
Diabetes mellitus  : Yes/No 
 
SYMPTOMS                 
Cough : 
 
Fever : 
 
Sputum : 
 
Chestpain : 
 Haemoptysis : 
 
Wheeze : 
 
Contact history of Tuberculosis : yes/no 
 
Previous history of Tuberculosis treatment:  
                                                             If yes, Number of times of treatment, 
                                                             Duration of treatment, 
                                                              Regular /irregular 
   
GENERAL EXAMINATION    :         BMI 
                                                          Anaemia 
                                                          Lymphadenopathy 
                                                          Jaundice 
                                                          Spine 
                                                          Pedal edema  
VITALS: 
PR:                          BP: 
RR:              Temp: 
EXAMINATION OF RESPIRATORY SYSTEM: 
Inspection : 
 
Palpation : 
 
Percussion : 
 
Auscultation : 
 
PER ABDOMEN : 
 
CARDIOVASCULAR SYSTEM : 
 
CENTRAL NERVOUS SYSTEM : 
                                              
INVESTIGATIONS:     
Hemoglobin  : 
WBC Count  : 
Chest X-Ray  : 
MANTOUX  : 
SPUTUM for AFB : 
CULTURE AND SENSITIVITY FOR AFB: 
OTHER INVESTIGATIONS: 
FINAL DIAGNOSIS: 
 ANNEXURE – II 
CONSENT FORM  
 
 I Mr / Mrs / Miss / ____________________________ have understood 
the procedure read by the Doctors. I in my whole conscious awareness give 
consent for the procedure. I understand that the procedure is done in good 
faith for the best therapeutic results possible. I fully understand the 
consequences of the procedure. I can resign from the study at any point of 
time. 
        Signature  
 
Name  :  
 
Date and Time  
 
Signature of Research 
 
 
 
